- Home
- API vs KALV Comparison
API vs KALV Comparison
Compare API & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- KALV
- Stock Information
- Founded
- API 2013
- KALV N/A
- Country
- API United States
- KALV United States
- Employees
- API N/A
- KALV N/A
- Industry
- API Computer Software: Prepackaged Software
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- KALV Health Care
- Exchange
- API Nasdaq
- KALV Nasdaq
- Market Cap
- API 419.4M
- KALV 482.8M
- IPO Year
- API 2020
- KALV N/A
- Fundamental
- Price
- API $4.65
- KALV $8.86
- Analyst Decision
- API
- KALV Strong Buy
- Analyst Count
- API 0
- KALV 5
- Target Price
- API N/A
- KALV $27.67
- AVG Volume (30 Days)
- API 2.3M
- KALV 372.0K
- Earning Date
- API 11-25-2024
- KALV 12-24-2024
- Dividend Yield
- API N/A
- KALV N/A
- EPS Growth
- API N/A
- KALV N/A
- EPS
- API N/A
- KALV N/A
- Revenue
- API $134,844,000.00
- KALV N/A
- Revenue This Year
- API N/A
- KALV N/A
- Revenue Next Year
- API $8.09
- KALV N/A
- P/E Ratio
- API N/A
- KALV N/A
- Revenue Growth
- API N/A
- KALV N/A
- 52 Week Low
- API $1.65
- KALV $8.48
- 52 Week High
- API $6.64
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- API 48.85
- KALV 37.81
- Support Level
- API $4.21
- KALV $8.52
- Resistance Level
- API $6.64
- KALV $9.22
- Average True Range (ATR)
- API 0.67
- KALV 0.60
- MACD
- API -0.18
- KALV -0.04
- Stochastic Oscillator
- API 19.34
- KALV 10.50
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.